Exegenesis Bio and Modalis Therapeutics Corporation have announced a research collaboration and license agreement to advance MDL-201, a potential new treatment for Duchenne muscular dystrophy (DMD).
The collaboration brings together two technologies: Modalis’ CRISPR-GNDM epigenome editing platform and Exegenesis Bio’s EMC181 muscle-targeting AAV capsid. The agreement is expected to become effective on September 14, 2026.
A Different Approach to Duchenne Treatment
MDL-201 is being developed as a mutation-agnostic therapy, meaning that it is intended to potentially address a broad range of people with DMD rather than being limited to specific mutations.
Instead of attempting to replace the dystrophin gene, MDL-201 is designed to increase the production of utrophin, a protein that may partially complement the function of dystrophin in muscle.
The therapy uses Modalis’ proprietary CRISPR-GNDM (Guide Nucleotide-Directed Modulation) technology. Unlike traditional CRISPR approaches that can cut DNA, CRISPR-GNDM is designed to regulate gene expression without cutting both strands of DNA. For MDL-201, the goal is to selectively and sustainably activate the utrophin gene in muscle tissue.
Why the AAV Capsid Matters
One of the key parts of the collaboration is Exegenesis Bio’s EMC181 AAV capsid.
AAV capsids are the delivery components used to help transport gene therapy-related payloads into target cells. EMC181 has been engineered to have high tropism for muscle tissue, while also having liver-detargeting properties.
This combination is intended to increase delivery to muscle while reducing exposure to organs such as the liver. The companies believe this could potentially improve the therapeutic profile of MDL-201.
Combining Two Technologies
The collaboration combines Exegenesis Bio’s gene therapy delivery technology with Modalis’ CRISPR-GNDM payload and development experience.
Exegenesis Bio will contribute EMC181, while Modalis will use the capsid with its CRISPR-GNDM technology for MDL-201. The companies aim to improve muscle-targeted delivery and advance the program through nonclinical and eventually clinical development.
Modalis CEO Haruhiko Morita described the combination as bringing together durable utrophin activation and muscle-targeted delivery, with the long-term goal of developing a differentiated treatment approach that could potentially be applicable across different DMD mutations.
What This Means for the DMD Community
MDL-201 represents an approach that is different from therapies designed to directly replace or restore dystrophin.
However, it is important to understand that MDL-201 is still in research and development. The announcement describes plans to advance the program toward nonclinical and clinical development; it does not report clinical efficacy or safety results in patients.
The companies’ immediate objective is to combine their technologies and accelerate development of MDL-201. If the program progresses successfully, it could eventually represent another potential treatment strategy for Duchenne muscular dystrophy.
Daha Fazlasını Keşfedin: Duchenne Klinik Araştırma Yerleri Haritası
